Lantern Pharma Inc. (LTRN) stock
LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.02 (-6.17%)
Close on Nov 17, 2026Market cap $4.67MP/E –Yield –
Lantern Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Lantern Pharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.83M, down 40.0% year over year. For fiscal 2025 it was $11.51M, down 28.6% from the year before. The highest annual figure on record is $16.13M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.51M | -28.6% |
| FY2024 | Dec 31, 2024 | $16.13M | +35.6% |
| FY2023 | Dec 31, 2023 | $11.89M | +38.3% |
| FY2022 | Dec 31, 2022 | $8.60M | +13.6% |
| FY2021 | Dec 31, 2021 | $7.57M | +237.5% |
| FY2020 | Dec 31, 2020 | $2.24M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.57M | -35.6% |
| Q2 FY2026 | Jun 30, 2026 | $1.79M | -41.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.72M | -47.2% |
| Q4 FY2025 | Dec 31, 2025 | $2.74M | -35.7% |
| Q3 FY2025 | Sep 30, 2025 | $2.44M | -34.4% |
| Q2 FY2025 | Jun 30, 2025 | $3.07M | -21.1% |
| Q1 FY2025 | Mar 31, 2025 | $3.26M | -23.2% |
| Q4 FY2024 | Dec 31, 2024 | $4.27M | +19.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.72M | +68.2% |
| Q2 FY2024 | Jun 30, 2024 | $3.89M | +9.3% |
| Q1 FY2024 | Mar 31, 2024 | $4.25M | +66.5% |
| Q4 FY2023 | Dec 31, 2023 | $3.57M | +58.7% |
| Q3 FY2023 | Sep 30, 2023 | $2.21M | +214.7% |
| Q2 FY2023 | Jun 30, 2023 | $3.56M | +19.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.55M | -4.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.25M | +4.1% |
| Q3 FY2022 | Sep 30, 2022 | $702.30K | -76.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.99M | +156.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.66M | +108.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.16M | +60.4% |
| Q3 FY2021 | Sep 30, 2021 | $2.96M | +393.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.16M | +641.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.28M | +832.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.35M | – |
| Q3 FY2020 | Sep 30, 2020 | $600.77K | – |
| Q2 FY2020 | Jun 30, 2020 | $157.02K | – |
| Q1 FY2020 | Mar 31, 2020 | $137.10K | – |
See a number that looks wrong?